Jonathan Dorfman, Chief Legal Officer and Secretary of Teladoc Health, Inc., filed an initial statement of beneficial ownership on November 3, 2026, disclosing his holdings as of the event date of November 2, 2026.

Key Highlights

  • Role: Dorfman is identified in the filing as Chief Legal Officer and Secretary of Teladoc Health, Inc. (NYSE:TDOC).
  • Direct common stock: The filing reports 2,773 shares of common stock held directly.
  • Performance stock units: 232 performance stock units, earned March 1, 2026, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter, each converting to common stock on a one-for-one basis.
  • Restricted stock units - cliff vest: 7,500 restricted stock units granted March 1, 2025, vesting in full on March 1, 2028, converting to common stock on a one-for-one basis.
  • Additional RSU grants: Three separate RSU awards totaling 24,169 units across grants from March 19, 2024, March 1, 2025, and March 1, 2026, each with its own vesting schedule.

Dorfman's Initial Ownership Disclosure at Teladoc Health

According to the filing, the event requiring the statement occurred on November 2, 2026, with the form submitted on November 3, 2026. Dorfman filed as a single reporting person in his capacity as an officer. The filing covers both non-derivative and derivative securities held directly.

In Table I, the filing discloses 2,773 shares of Teladoc Health common stock held directly. In Table II, four derivative positions are reported. The first is 232 performance stock units earned on March 1, 2026, vesting one-third on that date, with the balance vesting in eight substantially equal quarterly installments thereafter. The second is 1,668 restricted stock units remaining from a March 19, 2024 grant of 10,000 units, which began vesting one-third on March 19, 2025, with the remainder vesting in eight substantially equal quarterly installments beginning June 1, 2025. The third is 7,500 restricted stock units granted March 1, 2025, vesting in full on March 1, 2028. The fourth is 5,001 restricted stock units from a March 1, 2025 grant of 10,000, vesting one-third on March 1, 2026, with the remainder in eight substantially equal quarterly installments thereafter.

A fifth derivative position reports 10,000 restricted stock units granted March 1, 2026, vesting one-third on March 1, 2027, with the remainder vesting in eight substantially equal quarterly installments thereafter. The filing notes that all restricted stock units and performance stock units convert to shares of TDOC common stock on a one-for-one basis.

What Was Disclosed

Jonathan Dorfman submitted an initial beneficial ownership statement as Chief Legal Officer and Secretary of Teladoc Health, Inc., reporting 2,773 direct common shares and five derivative security positions comprising performance stock units and restricted stock units across multiple grant dates.